|Sonia M. Vallabh
Sonia’s scientific mission is to develop a treatment for prion disease. Besides therapeutic development, her research focuses on the biomarkers, models, tools, assays, patient cohorts, and datasets that will enable translation of therapeutics in the clinic. She earned her Ph.D. from Harvard in Biological and Biomedical Sciences, under Stuart Schreiber. Sonia also holds a J.D. from Harvard Law School. She retrained as a scientist after learning in 2011 that she had inherited the PRNP D178N mutation that causes genetic prion disease, and had claimed her mother’s life the year before. Outside of the lab, Sonia also co-runs the scientific nonprofit Prion Alliance.
|Eric Vallabh Minikel
Eric is Sonia’s husband. He followed Sonia into biomedicine to join the quest for a cure. He trained on human genomics in the MacArthur Lab and on chemical biology in the Schreiber Lab and earned his Ph.D. in Biological and Biomedical Sciences from Harvard. He blogs at CureFFI.org and tweets as @cureffi.
|Andrew G. Reidenbach
Andrew is a research scientist working on discovering small-molecule therapeutics for prion disease using a blend of high-throughput screening and focused biochemistry. He also co-leads efforts in Professor Stuart Schreiber’s laboratory to identify small-molecule binders of genetically validated therapeutic targets using novel DNA-encoded libraries. Prior to joining the Broad Institute, he earned a Ph.D. in biochemistry in the lab of Professor Dave Pagliarini at the University of Wisconsin–Madison.
Meredith is a research associate working on in vivo characterization of therapeutic drug activity and the validation of novel chemical assays which will ultimately aid in the treatment of prion disease. She graduated from University of Texas at Dallas in 2019 with a B.S. in Biochemistry. Previously, she spent two years working as an undergraduate research assistant investigating the effect of stress on memory consolidation in anxiety disorders.
Juliana is a postdoctoral associate studying the effects of prion protein-lowering therapy in vivo. Prior to working at the Broad Institute, she earned her Ph.D. in Molecular Biophysics and Biochemistry in Dr. Tony Koleske’s Lab at Yale University, where she studied mechanisms of actin regulation in dendritic spines.
Taylor is a research associate assisting in studying the effects of prion protein-lowering therapy in vivo. She graduated from James Madison University in 2021 with a B.S. in Biology with a minor in Pre-Professional Health studies and a concentration in neuroscience. Previously, she spent two years as an undergraduate research assistant studying the tunable band gap potentials of c3 heme cytochrome mutants in order to work towards creating a conventional semiconductor.
- Prof. Cristina Nonato. Visiting scholar 2017-2018. Professor, University of São Paolo.
- Francesca Pavlovici. Intern 2017. PhD Student, University of California Santa Cruz.
- Stacy G. Guzman. Intern 2017. Medical Student, University of Pennsylvania.
- Rishi N. Shah. Intern 2016. Cyber Operations Officer, U.S. Army.